Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression.
Atala A. Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression. J Urol. 2017 01; 197(1):154-155.